ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®.

Company profile
Ticker
CDXC
Exchange
Website
CEO
Robert Fried
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CODY RESOURCES, INC.
SEC CIK
Corporate docs
Subsidiaries
ChromaDex, Inc. • ChromaDex International, Inc. • ChromaDex Analytics, Inc. • ChromaDex Europa B.V. • ChromaDex UK Limited • Asia Pacific Scientific, Inc. • ChromaDex Asia Limited • ChromaDex Asia Pacific Ventures Limited • ChromaDex Trading (Shanghai) Co., Ltd. ...
IRS number
262940963
CDXC stock data
News

Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2022
11 Aug 22
B. Riley Securities Downgrades ChromaDex to Neutral, Lowers Price Target to $2.4
11 Aug 22
12 Health Care Stocks Moving In Thursday's Pre-Market Session
11 Aug 22
ChromaDex: Q2 Earnings Insights
10 Aug 22
Earnings Scheduled For August 10, 2022
10 Aug 22
Press releases
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
10 Aug 22
ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
2 Aug 22
ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)
7 Jul 22
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)
15 Jun 22
Thinking about buying stock in Nio, Redbox Entertainment, Agora, Chromadex, or Beyondspring?
10 Jun 22
Analyst ratings and price targets
Current price
Average target
$6.50
Low target
$6.00
High target
$7.00
HC Wainwright & Co.
Maintains
$7.00
Investment data
Securities sold
Number of investors
Calendar
10 Aug 22
11 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.07M | 17.07M | 17.07M | 17.07M | 17.07M | 17.07M |
Cash burn (monthly) | 1.31M | 1.81M | 2.13M | 2.36M | 1.28M | 1.82M |
Cash used (since last report) | 1.84M | 2.55M | 3M | 3.32M | 1.8M | 2.57M |
Cash remaining | 15.23M | 14.53M | 14.08M | 13.76M | 15.27M | 14.5M |
Runway (months of cash) | 11.7 | 8.0 | 6.6 | 5.8 | 12.0 | 8.0 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Jun 22 | Hoi Shuen Solina Holly Chau | Common Stock | Buy | Acquire P | Yes | No | 1.6636 | 60,037 | 99.88K | 6,925,641 |
16 Jun 22 | Wang Yu Gary Ng | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 20,000 | 32.8K | 20,000 |
16 Jun 22 | Kristin Patrick | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 20,000 | 32.8K | 20,000 |
16 Jun 22 | Ann Cohen | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 20,000 | 32.8K | 20,000 |
16 Jun 22 | Rubin Steven D | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 20,000 | 32.8K | 20,000 |
Institutional ownership, Q1 2022
54.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 86 |
Opened positions | 13 |
Closed positions | 13 |
Increased positions | 18 |
Reduced positions | 31 |
13F shares | Current |
---|---|
Total value | 144.95M |
Total shares | 36.88M |
Total puts | 61K |
Total calls | 149.4K |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Hoi Shuen Solina Holly Chau | 5.96M | $38.73M |
Pioneer Step | 5.96M | $31.58M |
Yong Rong | 4.07M | $10.03M |
Li Ka Shing | 3.47M | $12.97M |
BLK Blackrock | 3.15M | $7.76M |
Vanguard | 2.78M | $6.84M |
Tieton Capital Management | 1.43M | $3.52M |
ICONIQ Capital | 1.3M | $3.18M |
Phillip MD Frost Et Al | 1.23M | $11.82M |
STT State Street | 932.53K | $2.29M |
Financial report summary
?Risks
- The COVID-19 pandemic has adversely affected, and is expected to continue to pose risks to, our business, results of operations, financial condition and cash flows, and other epidemics or outbreaks of infectious diseases may have a similar impact.
- Global, market and economic conditions may negatively impact our business, financial condition and share price.
- We have a history of operating losses, may need additional financing to meet our future long-term capital requirements and may be unable to raise sufficient capital on favorable terms or at all.
- Our material cash requirements will depend on many factors.
- Interruptions in our relationships or declines in our business with major customers could materially harm our business and financial results.
- Our future success largely depends on sales of our Tru Niagen® product.
- Changes in our business strategy, including entering the consumer product market, or restructuring of our businesses may increase our costs or otherwise affect the profitability of our businesses.
- The success of our consumer product and ingredient business is linked to the size and growth rate of the vitamin, mineral and dietary supplement market and an adverse change in the size or growth rate of that market could have a material adverse effect on us.
- The future growth and profitability of our consumer product business will depend in large part upon the effectiveness and efficiency of our marketing efforts and our ability to select effective markets and media in which to market and advertise.
- We face significant competition, including changes in pricing.
- Many of our competitors are larger and have greater financial and other resources than we do.
- Litigation may harm our business.
- Our sales and results of operations for our analytical reference standards and services segment depend on our customers’ research and development efforts and their ability to obtain funding for these efforts.
- Our operating results may fluctuate significantly as a result of a variety of factors, many of which are outside of our control.
- We may need to increase the size of our organization, and we can provide no assurance that we will successfully expand operations or manage growth effectively.
- The insurance industry has become more selective in offering some types of coverage and we may not be able to obtain insurance coverage in the future.
- We may bear financial risk if we underprice our contracts or overrun cost estimates.
- If we experience a significant disruption in our information technology systems or if we fail to implement new systems and software successfully, our business could be adversely affected.
- If we are unable to maintain sales, marketing and distribution capabilities or maintain arrangements with third parties to sell, market and distribute our products, our business may be harmed.
- Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.
- We are subject to financial and operating covenants in our business financing agreement with Western Alliance Bank, as amended (Credit Agreement) and any failure to comply with such covenants, or obtain waivers in the event of non-compliance, could limit our borrowing availability under the Credit Agreement, resulting in our being unable to borrow under the Credit Agreement and materially adversely impact our liquidity. In addition, our operations may not provide sufficient cash to meet the repayment obligations of debt incurred under the Credit Agreement.
- Our business could be negatively impacted by cyber security threats, including without limitation a material interruption to our operations including our clinical trials, harm to our reputation, significant fines, penalties and liabilities, breach or triggering of data protection laws, privacy policies and data protection obligations, or a loss of customers or sales.
- Unfavorable publicity or consumer perception of our products and any similar products distributed by other companies could have a material adverse effect on our business.
- We utilize ingredients and components for our products from foreign suppliers, and may be negatively affected by the risks associated with international trade and importation issues.
- We may never develop any additional products to commercialize.
- We may not be able to partner with others for technological capabilities and new products and services.
- If we fail to maintain adequate quality standards for our products and services, our business may be adversely affected and our reputation harmed.
- If we experience product recalls, we may incur significant and unexpected costs, and our business reputation could be adversely affected.
- Demand for our products and services are subject to the commercial success of our customers’ products, which may vary for reasons outside our control.
- We rely on single or a limited number of third-party suppliers for the raw materials required to produce our products.
- Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain and may be inadequate, which would have a material and adverse effect on us.
- Our patents and licenses may be subject to challenge on validity grounds, and our patent applications may be rejected.
- We may become subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from developing our products, require us to obtain licenses from third parties or to develop non-infringing alternatives and subject us to substantial monetary damages.
- The prosecution and enforcement of patents licensed to us by third parties are not within our control. Without these technologies, our products may not be successful and our business would be harmed if the patents were infringed on or misappropriated without action by such third parties.
- We are currently engaged in substantial and complex litigation with Elysium Health, Inc. and Elysium Health LLC (collectively, "Elysium"), the outcome of which could materially harm our business and financial results.
- We may be subject to damages resulting from claims that we, our employees, or our independent contractors have wrongfully used or disclosed alleged trade secrets of others.
- We are subject to regulation by various federal, state and foreign agencies that require us to comply with a wide variety of regulations, including those regarding the manufacture of products, advertising and product label claims, the distribution of our products and environmental matters. Failure to comply with these regulations could subject us to fines, penalties and additional costs.
- Government regulations of our customer’s business are extensive and are constantly changing. Changes in these regulations can significantly affect customer demand for our products and services.
- Changes in government regulation or in practices relating to the pharmaceutical, dietary supplement, food and cosmetic industry could decrease the need for the services we provide.
- If we should in the future become required to obtain regulatory approval to market and sell our goods we will not be able to generate any revenues until such approval is received.
- Compliance with stringent and changing global privacy and data security laws and regulations could result in additional costs and liabilities to us or inhibit our ability to collect and, if applicable, process data globally, and the failure or perceived failure to comply with such laws and regulations could have a material adverse effect on our business, financial condition or results of operations.
- The market price of our common stock may be volatile and adversely affected by several factors.
- We have not paid cash dividends in the past and do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.
- Our ability to use our net operating loss (NOL) carryforwards and certain other tax attributes may be limited.
- We have a significant number of outstanding options and unvested restricted stock units. Future sales of these shares could adversely affect the market price of our common stock.
- Our bylaws, as amended (Bylaws) provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
- We may become involved in securities class action litigation that could divert management’s attention and harm our business.
- Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.
- Our shares of common stock may be thinly traded, so you may be unable to sell at or near ask prices or at all.
- Stockholders may experience significant dilution if future equity offerings are used to fund operations or acquire complementary businesses.
Management Discussion
- (1) Includes approximately 0.2 million nonvested shares of restricted stock for the year ended December 31, 2021 and December 31, 2020 which are participating securities that feature voting and dividend rights.
- (2) Excluded from the computation of loss per share as their impact is antidilutive.
- Net Sales. Net sales consist of gross sales less discounts and returns. Our total net sales grew from $21.2 million in 2017 to $67.4 million in 2021, representing a 26% compound annual growth rate.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Good
|
New words:
advocacy, advocate, affiliated, anniversary, begun, Blue, burn, campaign, certainty, Chau, Chiba, China, Chinese, climate, Connecticut, considerable, coupled, Crystal, deadline, designee, deviate, domestic, drove, equitable, ERTC, ESG, focused, formation, fulfillment, Hat, headcount, hold, holding, House, Idea, indirectly, influential, JV, Ka, Lake, Li, Macau, Mainland, mission, month, nominal, ostensibly, overseeing, path, payroll, policy, PRC, preferential, properly, representing, repurchase, Shing, society, Solina, spanning, sporadic, stakeholder, strength, Sun, swift, Taikuk, Taiwan, Territory, Treasury, undermine, unpatentable, unrestricted, venture
Removed:
accrued, collective, Farr, Frank, Jaksch, Jr, Kevin, payable, posted, reclassified, relate, testing
Financial reports
Current reports
8-K
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
10 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
17 Jun 22
8-K
Departure of Directors or Certain Officers
9 Jun 22
8-K
ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China
19 May 22
8-K
ChromaDex Corporation Reports First Quarter 2022 Financial Results
12 May 22
8-K
Departure of Directors or Certain Officers
15 Apr 22
8-K
Departure of Directors or Certain Officers
15 Apr 22
8-K
Departure of Directors or Certain Officers
11 Apr 22
8-K
Departure of Directors or Certain Officers
8 Apr 22
8-K
Regulation FD Disclosure
23 Mar 22
Registration and prospectus
424B3
Prospectus supplement
22 Apr 21
D
$25M in equity, sold $25M, 1 investor
2 Mar 21
S-8
Registration of securities for employees
18 Aug 20
424B5
Prospectus supplement for primary offering
26 Jun 20
424B3
Prospectus supplement
3 Jun 20
S-3
Shelf registration
21 May 20
D
$5M in equity, sold $5M, 2 investors
20 May 20
424B3
Prospectus supplement
2 Oct 19
Proxies
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEFA14A
Additional proxy soliciting materials
21 Apr 21
DEFA14A
Additional proxy soliciting materials
21 Apr 20
DEFA14A
Additional proxy soliciting materials
23 Apr 19
DEFA14A
Additional proxy soliciting materials
27 Apr 18
DEF 14A
Definitive proxy
27 Apr 18
Other
EFFECT
Notice of effectiveness
23 Apr 21
CORRESP
Correspondence with SEC
20 Apr 21
UPLOAD
Letter from SEC
24 Mar 21
CT ORDER
Confidential treatment order
28 Oct 20
CT ORDER
Confidential treatment order
11 Sep 20
CT ORDER
Confidential treatment order
17 Aug 20
EFFECT
Notice of effectiveness
8 Jul 20
CORRESP
Correspondence with SEC
23 Jun 20
UPLOAD
Letter from SEC
17 Jun 20
EFFECT
Notice of effectiveness
2 Jun 20
Ownership
SC 13G/A
ChromaDex / Yong Rong ownership change
24 Jun 22
4
ChromaDex / Wing Tak Wendy YU ownership change
21 Jun 22
4
ChromaDex / Steven D Rubin ownership change
21 Jun 22
4
ChromaDex / Ann Cohen ownership change
21 Jun 22
4
ChromaDex / Kristin Patrick ownership change
21 Jun 22
4
ChromaDex / Wang Yu Gary Ng ownership change
21 Jun 22
4
ChromaDex / Hoi Shuen Solina Holly Chau ownership change
21 Jun 22
3
ChromaDex / Hoi Shuen Solina Holly Chau ownership change
21 Jun 22
SC 13D/A
ChromaDex / SHING LI KA ownership change
20 May 22
SC 13D/A
ChromaDex / Pioneer Step ownership change
20 May 22
Transcripts
2022 Q2
Earnings call transcript
11 Aug 22
2022 Q1
Earnings call transcript
13 May 22
2021 Q4
Earnings call transcript
10 Mar 22
2021 Q3
Earnings call transcript
4 Nov 21
2021 Q2
Earnings call transcript
4 Aug 21
2021 Q1
Earnings call transcript
9 May 21
2020 Q4
Earnings call transcript
11 Mar 21
2020 Q3
Earnings call transcript
4 Nov 20
2020 Q2
Earnings call transcript
9 Aug 20
2020 Q1
Earnings call transcript
11 May 20
Reddit threads
Daily Discussion Thread - August 10th, 2022
10 Aug 22
Daily Discussion Thread - August 9th, 2022
9 Aug 22
Daily Discussion Thread - August 2nd, 2022
2 Aug 22
Daily Discussion Thread - August 1st, 2022
1 Aug 22
Daily Discussion Thread - May 12th, 2022
12 May 22
Daily Discussion Thread - May 11th, 2022
11 May 22
Daily Plays March 31, 2022
31 Mar 22
Daily Plays March 29, 2022
29 Mar 22
Daily Discussion Thread - March 9th, 2022
9 Mar 22
Daily Discussion Thread - March 8th, 2022
8 Mar 22